Variable | Summary (N = 272) |
Age at start of SRT (years) | 67 (45 - 85) |
Pre-RP PSA (ng/ml) | 8.4 (0.0 - 219.0) |
Pre-SRT (PSA (ng/ml) | 0.6 (0.2 - 21.9) |
Pathological tumor stage |
|
T2 | 136 (50%) |
T3a | 88 (32%) |
T3b | 46 (17%) |
T4 | 1 (<1%) |
Gleason score |
|
1 - 6 | 101 (42%) |
7 | 108 (45%) |
8 - 10 | 29 (12%) |
Surgical margin |
|
Positive | 145 (54%) |
Negative | 123 (46%) |
SRT dose (Gy) | 66.6 (54.0 - 72.4) |
Visit interval (months) start of SRT to 1st visit (N = 272) | 4.7 (0.7 - 13.8) |
1st to 2nd visit (N = 118 patients with 2 visits) | 3.7 (0.1 - 20.4) |
2nd to 3rd visit (N = 55 patients with 3 visits) | 4.4 (1.0 - 13.3) |
3rd to 4th visit (N = 33 patients with 4 visits) | 4.6 (1.0 - 16.3) |
4rd to 5th visit (N = 14 patients with 5 visits) | 4.6 (1.1 - 12.6) |
5th to 6th visit (N = 9 patients with 6 visits) | 7.2 (1.1 - 11.0) |
Start of SRT to lowest PSA measurement (months) | 6.3 (1.3 - 79.1) |